JP2013526544A5 - - Google Patents

Download PDF

Info

Publication number
JP2013526544A5
JP2013526544A5 JP2013510307A JP2013510307A JP2013526544A5 JP 2013526544 A5 JP2013526544 A5 JP 2013526544A5 JP 2013510307 A JP2013510307 A JP 2013510307A JP 2013510307 A JP2013510307 A JP 2013510307A JP 2013526544 A5 JP2013526544 A5 JP 2013526544A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
optionally substituted
disorder
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013510307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526544A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/036308 external-priority patent/WO2011143466A1/en
Publication of JP2013526544A publication Critical patent/JP2013526544A/ja
Publication of JP2013526544A5 publication Critical patent/JP2013526544A5/ja
Withdrawn legal-status Critical Current

Links

JP2013510307A 2010-05-12 2011-05-12 複素環スルホンmGluR4アロステリック増強剤、組成物、および神経機能不全を治療する方法 Withdrawn JP2013526544A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33392610P 2010-05-12 2010-05-12
US61/333,926 2010-05-12
PCT/US2011/036308 WO2011143466A1 (en) 2010-05-12 2011-05-12 Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Publications (2)

Publication Number Publication Date
JP2013526544A JP2013526544A (ja) 2013-06-24
JP2013526544A5 true JP2013526544A5 (US07794700-20100914-C00152.png) 2014-06-19

Family

ID=44914713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510307A Withdrawn JP2013526544A (ja) 2010-05-12 2011-05-12 複素環スルホンmGluR4アロステリック増強剤、組成物、および神経機能不全を治療する方法

Country Status (13)

Country Link
US (1) US9192603B2 (US07794700-20100914-C00152.png)
EP (1) EP2568809A4 (US07794700-20100914-C00152.png)
JP (1) JP2013526544A (US07794700-20100914-C00152.png)
KR (1) KR20130079429A (US07794700-20100914-C00152.png)
CN (1) CN102939006A (US07794700-20100914-C00152.png)
AU (1) AU2011252974A1 (US07794700-20100914-C00152.png)
BR (1) BR112012028894A2 (US07794700-20100914-C00152.png)
CA (1) CA2798514A1 (US07794700-20100914-C00152.png)
IL (1) IL222854A0 (US07794700-20100914-C00152.png)
MX (1) MX2012013031A (US07794700-20100914-C00152.png)
RU (1) RU2012154447A (US07794700-20100914-C00152.png)
SG (1) SG185414A1 (US07794700-20100914-C00152.png)
WO (1) WO2011143466A1 (US07794700-20100914-C00152.png)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010027762A1 (en) 2008-09-04 2010-03-11 Boehringer Ingelheim International Gmbh Indolizine inhibitors of leukotriene production
JP2012516355A (ja) 2009-01-28 2012-07-19 ヴァンダービルト ユニバーシティー mGLuR4アロステリック増強剤としての置換された1,1,3,3−テトラオキシドベンゾ[d][1,3,2]ジチアゾール、組成物、および神経機能不全を治療する方法
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8420655B2 (en) 2009-12-04 2013-04-16 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
SG187549A1 (en) 2010-08-16 2013-03-28 Boehringer Ingelheim Int Oxadiazole inhibitors of leukotriene production
EP2609092B1 (en) 2010-08-26 2015-04-01 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
BR112013008638A2 (pt) 2010-09-23 2016-06-21 Boehringer Ingelheim Int inibidores de oxadiazol de produção de leucotrieno
WO2012040137A1 (en) 2010-09-23 2012-03-29 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
JP5928958B2 (ja) 2010-10-29 2016-06-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
US8772304B2 (en) 2010-11-01 2014-07-08 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
US9073895B2 (en) 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
WO2013186089A2 (en) 2012-06-14 2013-12-19 Basf Se Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests
AU2014327504B2 (en) * 2013-09-25 2018-01-04 F. Hoffmann-La Roche Ag Ethynyl derivatives
WO2016115272A1 (en) 2015-01-13 2016-07-21 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10526323B2 (en) 2015-01-30 2020-01-07 Vanderbilt University Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2016123627A1 (en) 2015-01-30 2016-08-04 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
WO2016179351A1 (en) 2015-05-05 2016-11-10 Northwestern University Treatment of levodopa-induced dyskinesias
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US10294222B2 (en) 2016-09-01 2019-05-21 Vanderbilt University Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10710997B2 (en) 2016-09-01 2020-07-14 Vanderbilt University Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10968227B2 (en) 2016-11-08 2021-04-06 Vanderbilt University Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2018089544A1 (en) 2016-11-08 2018-05-17 Vanderbilt University Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2018130443A1 (de) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
AU2018207776B2 (en) 2017-01-10 2021-06-17 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
WO2019006157A1 (en) 2017-06-28 2019-01-03 Vanderbilt University QUINOLINE PYRIDINE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIALIZERS, COMPOSITIONS, AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTIONS
CA3072493A1 (en) 2017-08-16 2019-02-21 Vanderbilt University Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
US11724997B2 (en) 2018-03-01 2023-08-15 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN114258391A (zh) 2019-04-03 2022-03-29 阿里戈斯治疗公司 吡咯化合物
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
US20230247994A1 (en) 2020-07-02 2023-08-10 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE21393T1 (de) 1982-01-22 1986-08-15 Basf Ag Thiadiazolderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses.
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6468977B1 (en) 1998-03-02 2002-10-22 Apotex Inc. Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
US6162791A (en) 1998-03-02 2000-12-19 Apotex Inc. Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
AU743489B2 (en) 1998-03-19 2002-01-24 Pharmacia & Upjohn Company 1,3,4-thiadiazoles useful for the treatment of CMV infections
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
US20060166972A1 (en) 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
EP1983980A4 (en) 2006-01-25 2010-05-05 Synta Pharmaceuticals Corp THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
WO2008014199A2 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
CN101516839A (zh) 2006-09-25 2009-08-26 贝林格尔.英格海姆国际有限公司 调节cb2受体的化合物
WO2008049864A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
CA2741400A1 (en) * 2008-09-16 2010-03-25 Merck & Co., Inc. Sulfonamide derivative metabotropic glutamate r4 ligands

Similar Documents

Publication Publication Date Title
JP2013526544A5 (US07794700-20100914-C00152.png)
JP2013519684A5 (US07794700-20100914-C00152.png)
JP2013519685A5 (US07794700-20100914-C00152.png)
RU2012139491A (ru) Бензизоксазолы и азабензизоксазолы как аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
RU2012154447A (ru) Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
JP2013545730A5 (US07794700-20100914-C00152.png)
JP2013526609A5 (US07794700-20100914-C00152.png)
JP2011515482A5 (US07794700-20100914-C00152.png)
RU2012114770A (ru) АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ
HRP20160135T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka
JP2016185995A5 (US07794700-20100914-C00152.png)
JP2013525444A5 (US07794700-20100914-C00152.png)
RU2012121631A (ru) АРИЛ- И ГЕТЕРОАРИЛСУЛЬФОНЫ КАК АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ
JP2015501783A5 (US07794700-20100914-C00152.png)
JP2013522326A5 (US07794700-20100914-C00152.png)
JP2013503909A5 (US07794700-20100914-C00152.png)
JP2013536833A5 (US07794700-20100914-C00152.png)
JP2020531454A5 (US07794700-20100914-C00152.png)
JP2014532730A5 (ja) オピオイド受容体の調節物質およびそれを含む薬学的組成物
HRP20160545T1 (hr) Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink
JP2012531402A5 (US07794700-20100914-C00152.png)
JP2020503246A5 (US07794700-20100914-C00152.png)
JP2015500223A5 (US07794700-20100914-C00152.png)
JP2015516988A5 (US07794700-20100914-C00152.png)
JP2014509653A5 (US07794700-20100914-C00152.png)